Results 171 to 180 of about 1,917,601 (292)

DOMINICA protocol: A study of benralizumab for severe eosinophilic asthma in children. [PDF]

Pediatr Allergy Immunol
Guilbert TW, Jison M, Sjö LB, Werkström V, Grindebacke H, Durżyński T, Lal A, Grigg J.   +7 more
europepmc   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Sequential autoimmune and neoplastic manifestations during long-term benralizumab therapy for severe eosinophilic asthma: A descriptive case report. [PDF]

Respir Med Case Rep
Shimizu A, Hino M, Kubota K, Tanaka Y, Takeno M, Takei H, Terasaki Y, Seike M.   +7 more
europepmc   +1 more source

Diagnostic Delay in Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors and Implications for Earlier Recognition

Allergy, EarlyView.
This study aimed to assess diagnostic delay among patients with eosinophilic granulomatosis with polyangiitis (EGPA) and identify clinical characteristics associated with delayed recognition. EGPA diagnosis was delayed by nearly five years from symptom onset in this single‐center cohort.
Vani Mulkareddy, Kalena Liu, Shreya Mandloi, Kelsey Limage, Samuel R. Shing, Gurston G. Nyquist, Jessica Most, David Kennedy, Elina Toskala, Damaris Pena‐Evertz   +9 more
wiley   +1 more source

Targeting Eosinophils in Asthmatic Inflammation: Benefits and Drawbacks

Journal of Inflammation Research
David Broide Department of Medicine, University of California San Diego, La Jolla, CA, 92093-0635, USACorrespondence: David Broide, Department of Medicine, University of California San Diego, La Jolla, CA, 92093-0635, USA, Email dbroide@health.ucsd ...
Broide D
doaj  

Hemodynamic improvement but worsening hypoxemia after balloon pulmonary angioplasty: severe eosinophilic asthma unmasked in CTEPH. [PDF]

BMC Pulm Med
Fujii H, Isobe S, Tamura Y.
europepmc   +1 more source

Eosinophil Counts and Asthma Severity in Children [PDF]

Journal of Allergy and Clinical Immunology, 2017
Cristine S. Rosario, Monica L. Cat, Herberto J. Chong Neto, Carlos A. Riedi, Nelson A. Rosario   +4 more
openaire   +1 more source

Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

Allergy, EarlyView.
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard, Camille Braun, Éloise Antony, Émilie Roy, Marie‐Ève Gingras, François Graham, Anne Des Roches, Louis Paradis, Kathryn Samaan, Florence Gingras‐Lessard, Roxane Labrosse, Thomas Eiwegger, Philippe Bégin   +12 more
wiley   +1 more source

Predictive Factors And Treatments Associated with Clinical Remission in Severe Eosinophilic Asthma. [PDF]

J Inflamm Res
Lupia C, Marchi G, Chiarella E, Piazzetta GL, Lobello N, Crimi C, Poto R, Maglio A, Vatrella A, Pelaia G, Pelaia C.   +10 more
europepmc   +1 more source

The Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis

Allergy, EarlyView.
ABSTRACT Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...
Peter K. Smith, Nicholas P. West, Stanley Du Preez, Hugh A. Sampson, Peter W. Hellings, David Price, Liam O'Mahony, Carina Venter, Cezmi A. Akdis, Gil Yosipovitch   +9 more
wiley   +1 more source